The lower upfront cash is a clear negative for near-term value, but the increased CVR upside creates a binary catalyst tied to the Phase 2a GBM trial. Monitor enrollment updates for LSTA1-GBM-2A closely — the First Milestone ($1.25/share) could trigger by December 15, 2026 if enrollment completes. The non-tradeable CVRs mean holders must retain shares through closing to participate.
Price Chart
Executive Summary
Lisata Therapeutics amended its merger agreement with Kuva Labs, reducing the upfront cash consideration from $5.00 to $4.00 per share but increasing the maximum contingent value right (CVR) payout from $1.00 to $3.00 per share, split into a $1.25 milestone upon enrollment/completion of a Phase 2a GBM trial and a $1.75 milestone upon an NDA filing. The tender offer is set to commence June 1, 2026, with the outside date extended to July 6, 2026. This is a renegotiation that lowers guaranteed cash but offers higher potential upside tied to clinical and regulatory milestones.
Key Financial Metrics
Key Facts
- Upfront cash consideration reduced from $5.00 to $4.00 per share (a 20% decrease)
- Maximum CVR payout increased from $1.00 to $3.00 per share ($1.25 First Milestone + $1.75 Second Milestone)
- First Milestone: enrollment completion, 90% enrollment, or termination of Phase 2a GBM trial (LSTA1-GBM-2A)
- Second Milestone: filing/acceptance of an NDA for certepetide (formerly LSTA1/CEND-1)
- CVRs are non-tradeable and expire on the 7th anniversary of closing
- Tender offer to commence June 1, 2026; outside date extended to July 6, 2026
- Interest accrues at the lesser of 10% p.a. or SOFR+5% on late First Milestone payments
Financial Impact
Guaranteed cash per share reduced by $1.00 (20% decrease), offset by up to $2.00 additional contingent consideration per share. Total maximum consideration per share is $7.00 ($4.00 cash + $3.00 CVRs) vs. $6.00 previously ($5.00 cash + $1.00 CVR).
Risk Factors
- Phase 2a GBM trial may fail to enroll or be terminated without milestone achievement
- CVRs are non-tradeable and expire worthless if milestones are not met within 7 years
- Kuva Labs may not complete the tender offer or merger despite the amendment
- Regulatory approval for certepetide is uncertain and years away
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-023336 |
| Document: ef20075162_8k.htm | 0001140361-26-023336 |
| Document: ef20075162_ex2-1.htm | 0001140361-26-023336 |
| Document: 0001140361-26-023336-index-headers.html | 0001140361-26-023336 |
| Document: 0001140361-26-023336-index.html | 0001140361-26-023336 |
| Document: 0001140361-26-023336.txt | 0001140361-26-023336 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | DEF 14A | $1.00 | awaiting T+60 | — | $1.06 (−6.00%) |
Oct 14, 2026 12d ago | 8-K | $1.07 | awaiting T+60 | — | $1.06 (−0.93%) |
Sep 17, 2026 5w ago | 8-K | $1.74 | awaiting T+60 | — | $1.06 (−39.08%) |
Sep 17, 2026 5w ago | Press Release | $1.74 | awaiting T+60 | — | $1.06 (−39.08%) |
Aug 4, 2026 12w ago | 8-K | $1.14 | awaiting T+60 | — | $1.06 (+7.02%) |
Jul 24, 2026 13w ago | 8-K | $1.67 $1.00 | ▲ +40.12% | ▲ +43.41% | $1.06 (+36.53%) |
Jul 17, 2026 14w ago | 8-K | $3.60 $1.05 | ▼ −70.79% | ▼ −75.48% | $1.06 (−70.51%) |
Jun 10, 2026 19w ago | Press Release | $3.61 $1.64 | ▼ −54.57% | ▼ −61.15% | $1.06 (−70.64%) |
Jun 9, 2026 20w ago | 8-K | $3.46 $1.57 | ▲ +54.62% | ▲ +58.44% | $1.06 (+69.36%) |
Jun 1, 2026 21w ago | 8-K | $3.58 $1.74 | ▲ +51.40% | ▲ +52.63% | $1.06 (+70.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers